查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1827977

血糖监测设备市场（按设备类型、技术、应用、最终用户和分销管道）—全球预测 2025-2032

Glucose Monitoring Devices Market by Device Type, Technology, Application, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年血糖监测设备市场将成长至 217.4 亿美元，复合年增长率为 12.85%。

主要市场统计数据
基准年2024年 82.6亿美元
预计2025年 93.4亿美元
预测年份：2032年 217.4亿美元
复合年增长率（%） 12.85%

全面了解不断发展的血糖监测格局、技术进步、临床采用模式和相关人员的优先事项

血糖监测领域正在经历快速的技术和商业性变革，重塑临床医生、看护者和糖尿病患者的血糖监测方式。感测器小型化、数据连接和演算法分析方面的进步与护理路径的转变相融合，为慢性病管理创造了新的模式。本简介将核心驱动因素和框架假设进行综合，为更深入的分析奠定基础，涵盖市场动态、细分市场、区域差异和策略影响。

近年来，人们的关注点已从偶尔的指尖采血检测转向持续的即时监测模式，这种模式强调纵向数据和可操作的洞察。这种转变影响着设备设计、监管策略、报销参与度和最终用户体验。结果是，竞争环境日益激烈，老牌医疗设备製造商、专业的糖尿病技术公司和新兴的数位健康公司都在製定强调连结性、易用性和临床整合的提案。当相关人员考虑产品开发、临床证据产生和商业化路径时，清楚了解技术趋势和监管压力对于抵御短期衝击并实现持续应用至关重要。

深入探讨技术、监管和商业性变革的融合，重新定义血糖监测的产品价值和照护途径

一系列相互关联的变革正在重塑血糖监测领域，这些变革正在重新定义产品价值、护理服务和竞争优势。感测器精度的提升，加上更长的佩戴时间和微创的外形规格，正在将应用场景从传统的糖尿病管理扩展到预防性监测和手术全期护理。同时，可互通的资料生态系统和云端原生分析正在赋能远端监测、人口健康管理和决策支援等领域的全新服务，从而改变着设备製造商和软体合作伙伴的期望。

监管机构正在不断发展，以适应软体和自适应演算法作为医疗设备的应用，这增加了真实世界证据和上市后监管的重要性。付款方的支付方式也在发生变化，基于价值的基本契约和基于结果的报销模式在某些市场越来越受欢迎。这种系统性转变正迫使企业将其临床证据策略与商业模式结合，并投资于硬体、软体和服务的跨学科能力。因此，随着市场的成熟，那些整合以使用者为中心的设计、强大的临床检验和可扩展资料基础设施的领导者将拥有更优越的策略选择。

从策略角度评估 2025 年关税变化如何改变整个血糖监测价值链的供应链、采购决策和商业策略

2025年新关税的实施对整个血糖监测生态系统的供应链、筹资策略和定价决策产生了一系列连锁反应。依赖国际采购零件的製造商面临到岸成本上升的问题，导致许多製造商重新评估其采购布局和供应商多元化。对于在受影响国家以外拥有垂直整合製造业务的公司来说，关税环境激励他们加快在地化和区域供应商开发，以确保生产的连续性并管理单位经济效益。

除了直接成本压力外，关税还影响了产品组合和采购时机的策略选择。一些公司优先考虑利润率较高的订阅式服务和捆绑产品，以保护收益流免受设备价格暂时下跌的影响。医疗保健机构和大型采购商的应对措施是更新其采购框架，将整体拥有成本（而不仅仅是关键单位成本）纳入考虑。同时，由于製造商寻求记录产品来源和合规性，监管备案和供应链认证变得更加重要，这增加了产品上市的专案成本。累积效应是商业策略的重新平衡，转向弹性、供应商冗余以及产品蓝图与采购风险接受度的更紧密结合。

细粒度细分整合揭示了设备类型、技术选择、临床使用、最终用户设定和分销管道如何决定差异化创新和上市方法

透过对设备类型、技术、应用、最终用户和分销管道进行細項分析，可以揭示差异化的创新轨迹和应用趋势。依装置类型划分，连续血糖监测和闪光血糖监测与自我监测形成对比，而自我监测本身又根据临床工作流程和付款人要求分为个人型和专业型。侵入式方法（包括比色法和电化学安培法）继续与以皮下感测器为主导的微创方法以及利用光谱和经皮提取的非侵入式方法共存，每种方法都呈现出其独特的监管格局和用户体验权衡。

基于应用的细分强调，设备设计和服务模式是根据妊娠糖尿病护理、1 型糖尿病管理和 2 型糖尿病患者的需求量身定制的，临床证据和教育支持也随之变化。最终使用者细分将需求分为门诊、居家医疗环境，医院进一步分为私立和公立机构，具有不同的采购限制和临床通讯协定。最后，分销管道的差异决定了商业化策略，医院药局、网路商店（包括企业网站和电子商务平台）和零售药局（由连锁店和独立商店组成）实现了多样化的市场方法。总之，这些细分强调了产品设计、证据产生和商业性执行需要与目标客户群的需求和限制紧密结合。

区域资讯简报，解释地理管理体制、付款人结构和医疗保健提供模式如何为血糖监测的采用创造不同的途径

区域动态对监管途径、报销模式和采用率有着重大影响，从而在美洲、中东和非洲以及亚太地区形成了不同的战略要务。在美洲，临床医生主导的采用和早期付款人的参与推动了先进监测解决方案的快速普及，并强调与电子健康记录和远端监测平台的互通性。这种环境有利于那些能够无缝融入临床工作流程、展示临床结果并适应复杂报销框架的供应商。

欧洲、中东和非洲环境复杂多样，监管环境、公共采购惯例和医疗体系各自为政，因此需要製定灵活的上市计划，以适应各国在核准时间和付款人期望方面的差异。与当地经销商和临床医生的伙伴关係通常对于建立信任和调整证据包以适应当地标准至关重要。亚太市场频谱差异很大，竞争激烈的都市区更青睐支持远端医疗的解决方案，而价格竞争激烈的市场则强调具有成本效益的设备和可扩展的市场竞争模式。在所有地区，监管协调工作和跨境资料管治讨论将继续影响商业化策略和产品设计重点。

竞争格局评估，确定策略倡议、联盟模式和能力差距，以决定血糖监测生态系统的领导地位

血糖监测领域的竞争态势呈现混合格局，既有现有的医疗设备製造商，也有专业的糖尿病技术公司，以及带来软体和数据能力的跨产业参与企业。领先企业正大力投资感测器效能、使用者体验和临床证据，以捍卫其差异化地位；而敏捷的挑战者则专注于颠覆性的外形规格、定价模式和软体赋能服务。竞争中普遍存在的策略倡议包括：感测器和分析能力的垂直整合、扩大与支付方和医疗系统的伙伴关係，以及旨在加快互补技术上市时间的定向收购。

成功的公司将是那些能够平衡强大的临床检验与可扩展生产，并拥有清晰的商业化路径以满足医疗服务提供者、付款人和患者需求的公司。硬体团队和演算法开发人员之间的协同开发是提供有意义的洞察而非原始数据的先决条件。此外，与分销合作伙伴和数位健康平台的有效合作将提升覆盖范围和依从性，尤其是在居家照护环境中。随着行业的发展，协调跨职能能力并展示实际影响力的能力将决定哪些公司能够获得领导地位。

为製造商和相关人员提供实用的优先建议，以协调临床检验、商业化模式和营运弹性，实现永续优势

行业领导者应优先考虑一系列切实可行的行动，使产品开发、证据生成和商业化执行与不断变化的临床和付款人期望一致。首先，投资于将设备性能与患者和医疗保健系统有意义的结果联繫起来的临床研究，对于支持报销对话和实现产品差异化至关重要。为了补充临床证据，公司应开发模组化的商业模式，将设备、资讯服务和教育支援结合起来，以增强用户黏性并实现收益来源多元化。

在营运方面，企业必须透过供应商多元化、生产灵活性以及清晰的零件来源可追溯性来增强供应链的韧性。与数位健康平台和电子健康记录提供者建立策略伙伴关係，将加速其与临床工作流程的整合，并提升供应商感知价值。最后，企业必须建立上市后资料分析和自适应软体法规合规能力，以实现迭代改进和持续的法规合规性。将这些行动结合起来，将使企业能够抓住需求，同时管理不同市场的成本和监管压力。

用于评估设备技术、临床应用和商业动态的研究设计、资料来源和分析方法的透明描述

本研究结合了原厂药和二手资料，旨在对血糖监测现况进行严格且可重复的评估。原厂药包括对临床医生、采购主管和技术高管的结构化访谈，并辅以临床环境下的技术检验和观察性评估，以支持关于可用性和整合挑战的论述。二手资料研究则使用了同行评审的临床文献、监管文件和公开文件，建构了关于技术性能和监管趋势的坚实证据基础。

我们的分析方法结合了定性编码和访谈资料的主题综合，以确定反覆出现的策略重点；我们的技术评估则根据准确性、可穿戴性和资料互通性等临床标准对感测器模式进行了评估。我们透过跨多个资讯来源的三角测量检验了相关说法，并注意标记尚未出现证据的领域。我们承认这种方法有局限性，包括不同地区临床实践的差异以及技术创新的快速发展，这些因素可能会改变研究週期之间的竞争动态。在适当的情况下，我们建议进行能够反映可靠​​证据范围的研究，并强调进行有针对性的一手研究以减少不确定性的机会。

策略整合强调综合技术、证据和商业策略将如何决定哪些组织将创新转化为持续的临床和商业性影响

结论总结了报告的核心主题，并强调了对寻求驾驭不断发展的血糖监测领域的相关人员的策略意义。技术创新正在实现更丰富、更连续的数据集，从而支持更主动的慢性病管理，但要实现这一愿景，需要临床检验、监管策略和付款人参与之间的协调。成功将卓越硬体与扩充性数据分析和以用户为中心的设计相结合的市场参与企业，预计将在医疗保健领域实现广泛应用。

鑑于地缘政治和贸易中断会影响成本和供应的连续性，营运韧性和灵活的商业化模式同样重要。区域差异将持续存在，需要本地证据以及与临床医生和采购机构的合作。最终，竞争的胜负将取决于能否展示可衡量的临床和经济价值，同时为最终用户提供直觉、流畅的体验。果断采取行动应对这些优先事项的组织将最有能力将创新转化为对患者和系统层面有意义的成果。

目录

第一章 引言

第二章分析方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 连续血糖监测仪整合先进的机器学习演算法，用于预测血糖管理
  • 采用无痛、无需校准的非侵入式光学感测技术
  • 将穿戴式 CGM 设备无缝连接到远端医疗平台和远端患者监护
  • 设备製造商与数位治疗公司建立策略联盟，以加强糖尿病护理
  • 监管部门的核准加速了植入式长期连续血糖监测系统的开发
  • 对支援多供应商数据标准化的可互通血糖值监测平台的需求不断增长

第六章：美国关税的累积影响（2025年）

第七章：人工智慧（AI）的累积影响（2025年）

8. 血糖监测设备市场（依设备类型）

  • 持续血糖监测
    • 个人的
    • 商用
  • Flash血糖监测
  • 自我监测血糖

9. 血糖监测设备市场（依技术）

  • 侵入性
    • 比色分析
    • 电化学安培法
  • 微创
    • 皮下感应器
  • 非侵入性
    • 光谱学
    • 经皮提取

第 10 章血糖监测设备市场（按应用）

  • 妊娠糖尿病
  • 1型糖尿病
  • 2型糖尿病

第 11 章 血糖监测设备市场（依最终用户）

  • 门诊治疗
  • 居家医疗
  • 医院
    • 私立医院
    • 公立医院

第12章血糖监测设备市场（依通路）

  • 医院药房
  • 网路商店
    • 公司网站
    • 电商平台
  • 零售药局
    • 连锁药局
    • 独立药房

13. 血糖监测设备市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第14章血糖监测设备市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 血糖监测设备市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 市占率分析（2024年）
  • FPNV定位矩阵（2024年）
  • 竞争分析
    • Abbott Laboratories
    • Dexcom, Inc.
    • Medtronic plc
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Ascensia Diabetes Care Holdings AG
    • Senseonics Holdings, Inc.
    • ARKRAY, Inc.
    • Nipro Corporation
    • Sinocare, Inc.
Product Code: MRR-436B79517C57

The Glucose Monitoring Devices Market is projected to grow by USD 21.74 billion at a CAGR of 12.85% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 8.26 billion
Estimated Year [2025] USD 9.34 billion
Forecast Year [2032] USD 21.74 billion
CAGR (%) 12.85%

A comprehensive orientation to the evolving glucose monitoring landscape that frames technological advances, clinical adoption patterns, and stakeholder priorities

The landscape of glucose monitoring is undergoing rapid technological and commercial change, reshaping how clinicians, caregivers, and people with diabetes monitor glycemic control. Advances in sensor miniaturization, data connectivity, and algorithmic analytics are converging with shifting care pathways to create new models for chronic disease management. This introduction synthesizes core drivers and framing assumptions to set the stage for deeper analysis across market dynamics, segmentation, regional variation, and strategic implications.

In recent years, the focus has moved from episodic fingerstick testing toward continuous and real-time monitoring paradigms that emphasize longitudinal data and actionable insights. This transition has implications for device design, regulatory strategy, reimbursement engagement, and end-user experience. The result is a competitive environment where incumbent medical device manufacturers, specialized diabetes technology firms, and emerging digital health players are adjusting their propositions to emphasize connectivity, ease of use, and clinical integration. As stakeholders deliberate product development, clinical evidence generation, and commercialization pathways, a clear understanding of technological trends and regulatory pressures will be essential to navigate near-term disruptions and unlock sustained adoption.

An in-depth look at the converging technological, regulatory, and commercial shifts that are redefining product value and care pathways in glucose monitoring

The glucose monitoring sector is being transformed by a set of interrelated shifts that are redefining product value, care delivery, and competitive advantage. Sensor accuracy improvements combined with extended-wear and minimally invasive form factors are expanding use cases beyond conventional diabetes management into preventive monitoring and perioperative care. At the same time, interoperable data ecosystems and cloud-native analytics are enabling new services around remote monitoring, population health management, and decision support, which in turn alter expectations for device manufacturers and software partners.

Regulatory pathways are evolving to accommodate software as a medical device and adaptive algorithms, increasing emphasis on real-world evidence and post-market surveillance. Payer approaches are also changing, with value-based agreements and outcomes-based reimbursement models gaining traction in selective markets. These systemic shifts pressure firms to align clinical evidence strategies with commercial models and to invest in cross-disciplinary capabilities spanning hardware, software, and services. Consequently, leaders who integrate user-centered design, robust clinical validation, and scalable data infrastructures will capture outsized strategic options as the market matures.

A strategic appraisal of how tariff changes in 2025 reshaped supply chains, sourcing decisions, and commercial strategies across the glucose monitoring value chain

The imposition of new tariff measures in 2025 created a series of cascading effects on supply chains, sourcing strategies, and pricing decisions across the glucose monitoring ecosystem. Manufacturers relying on internationally sourced components faced increased landed costs, prompting many to re-evaluate sourcing footprints and supplier diversification. For companies with vertically integrated manufacturing outside affected jurisdictions, the tariff environment incentivized accelerated localization or regional supplier development to insulate production continuity and to manage unit economics.

Beyond direct cost pressures, tariffs influenced strategic choices around product configuration and procurement timing. Several firms prioritized higher-margin, subscription-based services and bundled offerings to protect revenue streams from one-time device price compression. Health systems and large purchasers reacted by updating procurement frameworks to incorporate total cost of ownership considerations rather than headline unit cost alone. Meanwhile, regulatory filings and supply chain certifications took on new importance as manufacturers sought to document origin and compliance, increasing programmatic costs for market entry. The cumulative effect has been a rebalancing of commercial playbooks toward resilience, supplier redundancy, and closer alignment between product roadmaps and procurement risk tolerance.

A granular segmentation synthesis revealing how device type, technology choices, clinical application, end-user settings, and distribution channels dictate differentiated innovation and go-to-market approaches

Segmentation analysis reveals differentiated innovation trajectories and adoption contours when examined across device type, technology, application, end user, and distribution channel. When framed by device type, Continuous Glucose Monitoring and Flash Glucose Monitoring contrast with Self Monitoring of Blood Glucose, while Continuous Glucose Monitoring itself bifurcates into Personal and Professional variants that address distinct clinical workflows and payer requirements. Technology distinctions further refine the landscape: Invasive approaches, including Colorimetric and Electrochemical Amperometric techniques, continue to coexist with Minimally Invasive options typified by subcutaneous sensors and Non Invasive modalities that leverage optical spectroscopy or transdermal extraction, each path presenting unique regulatory and user-experience trade-offs.

Application-based segmentation highlights that device design and service models are being tailored to the needs of gestational diabetes care, Type 1 diabetes management, and the larger population living with Type 2 diabetes, with clinical evidence and educational support varying accordingly. End-user segmentation splits demand across ambulatory care settings, home care environments, and hospital settings, where hospitals further divide into private and public institutions with different procurement constraints and clinical protocols. Finally, distribution channel distinctions shape commercialization strategies, with hospital pharmacies, online stores-encompassing company websites and e-commerce platforms-and retail pharmacies, made up of chain and independent outlets, enabling diverse go-to-market approaches. Taken together, these segmentation lenses demonstrate that product design, evidence generation, and commercial execution must be tightly aligned to the needs and constraints of targeted customer cohorts.

A regional intelligence overview explaining how geographic regulatory regimes, payer structures, and healthcare delivery models create distinct pathways for glucose monitoring adoption

Regional dynamics exert a material influence on regulatory pathways, reimbursement models, and adoption rates, producing distinct strategic imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, clinician-led adoption and early payer engagement have supported rapid uptake of advanced monitoring solutions, with an emphasis on interoperability with electronic health records and remote monitoring platforms. This environment has favored vendors who can demonstrate clinical outcomes and integrate seamlessly into clinician workflows while navigating complex reimbursement frameworks.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory standards, public procurement practices, and health system fragmentation require agile market-entry plans that account for national differences in approval timelines and payer expectations. Partnerships with local distributors and clinicians are often critical to build trust and to adapt evidence packages to local standards. The Asia-Pacific region features a broad spectrum of market maturity, with highly competitive urban centers advancing telehealth-enabled solutions and more price-sensitive markets emphasizing cost-effective devices and scalable distribution models. Across all regions, regulatory harmonization efforts and cross-border data governance debates will continue to shape commercialization strategies and product design priorities.

A competitive landscape assessment that identifies strategic moves, partnership patterns, and capability gaps that determine leadership in the glucose monitoring ecosystem

Competitive dynamics in glucose monitoring are characterized by a mix of established medical device manufacturers, specialized diabetes technology companies, and cross-sector entrants that bring software and data capabilities. Leading players have invested heavily in sensor performance, user experience, and clinical evidence to defend differentiated positions, while agile challengers focus on disruptive form factors, pricing models, and software-enabled services. Strategic initiatives observed across the competitive set include vertical integration of sensor and analytics capabilities, expansion of partnerships with payers and health systems, and targeted acquisitions to accelerate time to market for complementary technologies.

Companies that succeed are those that balance robust clinical validation with scalable manufacturing and a clear commercialization pathway that addresses the needs of providers, payers, and patients. Collaboration between hardware teams and algorithm developers has become a prerequisite for delivering meaningful insights rather than raw data. In addition, effective engagement with distribution partners and digital health platforms enhances reach and adherence, particularly in home care settings. As the industry evolves, the ability to orchestrate cross-functional capabilities and demonstrate real-world impact will determine which companies capture leadership positions.

Practical and prioritized recommendations for manufacturers and stakeholders to align clinical validation, commercialization models, and operational resilience for sustained advantage

Industry leaders should prioritize a set of pragmatic actions that align product development, evidence generation, and commercial execution to evolving clinical and payer expectations. First, investment in clinical studies that link device performance to meaningful patient and health system outcomes will be essential to support reimbursement dialogues and to differentiate offerings. Complementing clinical evidence, firms should develop modular commercial models that combine devices, data services, and educational support to increase stickiness and diversify revenue streams.

Operationally, companies must strengthen supply chain resilience through supplier diversification, manufacturing flexibility, and clear traceability of component origins. Strategic partnerships with digital health platforms and electronic health record providers will accelerate integration into clinical workflows and enhance perceived value among providers. Finally, organizations should build capability in post-market data analytics and regulatory compliance for adaptive software, enabling iterative improvement and sustained regulatory alignment. These combined actions will position firms to capture demand while managing cost and regulatory pressures across diverse markets.

A transparent explanation of research design, data sources, and analytical methods used to evaluate device technologies, clinical adoption, and commercial dynamics

This study synthesizes primary and secondary research approaches to provide a rigorous, reproducible assessment of the glucose monitoring landscape. Primary research included structured interviews with clinicians, procurement leaders, and technology executives, supplemented by technical validations and observational assessments in clinical environments to ground claims about usability and integration challenges. Secondary research drew on peer-reviewed clinical literature, regulatory documents, and public filings to construct a robust evidence base for technology performance and regulatory trends.

Analytical methods combined qualitative coding of interview data with thematic synthesis to identify recurring strategic priorities, while technology assessments evaluated sensor modalities against clinical criteria such as accuracy, wearability, and data interoperability. Care was taken to validate claims through triangulation across multiple sources and to flag areas where evidence remains emergent. Limitations of the approach are acknowledged, including variability in clinical practice across regions and the rapid pace of innovation that can shift competitive dynamics between research cycles. Where appropriate, recommendations reflect the degree of evidentiary confidence and highlight opportunities for targeted primary research to reduce uncertainty.

A strategic synthesis highlighting how integrated technology, evidence, and commercial strategies will determine which organizations convert innovation into durable clinical and commercial impact

The conclusion synthesizes the report's central themes and underscores the strategic implications for stakeholders seeking to navigate the evolving glucose monitoring environment. Technological innovation is enabling richer, continuous datasets that support more proactive chronic disease management, but realizing this promise requires alignment among clinical validation, regulatory strategy, and payer engagement. Market participants that successfully integrate hardware excellence with scalable data analytics and user-centered design will unlock broader adoption across care settings.

Operational resilience and adaptive commercialization models are equally important given geopolitical and trade disruptions that influence cost and supply continuity. Regional nuances will persist, demanding localized evidence and tailored engagement with clinicians and procurement entities. Ultimately, the competitive battleground will be defined by the ability to demonstrate measurable clinical and economic value while delivering an intuitive, low-friction experience for end users. Organizations that act decisively on these priorities will be best positioned to translate innovation into meaningful patient and system-level outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Continuous glucose monitors integrating advanced machine learning algorithms for predictive glycemic management
  • 5.2. Adoption of non-invasive optical sensing technology for pain free and calibration free glucose measurement
  • 5.3. Expansion of wearable CGM devices with seamless connectivity to telehealth platforms and remote patient monitoring
  • 5.4. Strategic partnerships between device manufacturers and digital therapeutics companies to enhance diabetes care
  • 5.5. Regulatory approvals accelerating development of implantable long term continuous glucose monitoring systems
  • 5.6. Rising demand for interoperable glucose monitoring platforms supporting multi vendor data standardization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Glucose Monitoring Devices Market, by Device Type

  • 8.1. Continuous Glucose Monitoring
    • 8.1.1. Personal
    • 8.1.2. Professional
  • 8.2. Flash Glucose Monitoring
  • 8.3. Self Monitoring Of Blood Glucose

9. Glucose Monitoring Devices Market, by Technology

  • 9.1. Invasive
    • 9.1.1. Colorimetric
    • 9.1.2. Electrochemical Amperometric
  • 9.2. Minimally Invasive
    • 9.2.1. Subcutaneous Sensors
  • 9.3. Non Invasive
    • 9.3.1. Optical Spectroscopy
    • 9.3.2. Transdermal Extraction

10. Glucose Monitoring Devices Market, by Application

  • 10.1. Gestational Diabetes
  • 10.2. Type 1 Diabetes
  • 10.3. Type 2 Diabetes

11. Glucose Monitoring Devices Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Home Care
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals

12. Glucose Monitoring Devices Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Stores
    • 12.2.1. Company Websites
    • 12.2.2. E Commerce Platforms
  • 12.3. Retail Pharmacies
    • 12.3.1. Chain Pharmacies
    • 12.3.2. Independent Pharmacies

13. Glucose Monitoring Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Glucose Monitoring Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Glucose Monitoring Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. Dexcom, Inc.
    • 16.3.3. Medtronic plc
    • 16.3.4. F. Hoffmann-La Roche AG
    • 16.3.5. Johnson & Johnson
    • 16.3.6. Ascensia Diabetes Care Holdings AG
    • 16.3.7. Senseonics Holdings, Inc.
    • 16.3.8. ARKRAY, Inc.
    • 16.3.9. Nipro Corporation
    • 16.3.10. Sinocare, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GLUCOSE MONITORING DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. GLUCOSE MONITORING DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GLUCOSE MONITORING DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBCUTANEOUS SENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBCUTANEOUS SENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBCUTANEOUS SENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBCUTANEOUS SENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBCUTANEOUS SENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBCUTANEOUS SENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONIT